Animal models for microbicide safety and efficacy testing

Current Opinion in HIV and AIDS

Volumn 8, Issue 4, 2013, Pages 295-303

  Veazey, Ronald S ^a  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

humanized mice; microbicide; mouse; mucosal transmission; nonhuman primate; vaginal transmission

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MICROBICIDE; NONOXINOL 9; PLACEBO; TENOFOVIR;

ANIMAL EXPERIMENT; ANTIVIRAL THERAPY; CHEMOPROPHYLAXIS; DISEASE MODEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRIMATE; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION; VOMITING;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-RETROVIRAL AGENTS; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, INFECTIOUS; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV INFECTIONS; HUMANS; MACACA MULATTA; RESEARCH DESIGN; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 84880331943     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328361d096     Document Type: Review

References (62)

1. Haase AT. Early events in sexual transmission of HIV and SIV and opportu-nities for interventions. Annu Rev Med 2011; 62:127-139.
2. Hillier SL, Moench T, Shattock R, et al. In vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39:1-8.
3. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463-472.
4. Gray RH, Tobian A, Kigozi G, et al. Commentary: male circumcision for prevention of heterosexual acquisition of HIV in men: perspective from a trial team. Int J Epidemiol 2010; 39:970-971.
5. Girard MP, Plotkin SA. HIV vaccine development at the turn of the 21st century. Curr Opin HIV AIDS 2012; 7:4-9.
6. Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nat Rev Microbiol 2012; 10:852-867.
7. Veazey RS, Shattock RJ, Klasse PJ, Moore JP. Animal models for microbicide studies. Curr HIV Res 2012; 10:79-87.
8. Van Rompay KK. The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. AIDS Res Hum Retroviruses 2012; 28:16-35.
9. Zhang L, Su L. HIV-1 immunopathogenesis in humanized mouse models. Cell Mol Immunol 2012; 9:237-244.
10. Kelly CG, Shattock RJ. Specific microbicides in the prevention of HIV infection. J Intern Med 2011; 270:509-519.
11. Kersh EN, Luo W, Zheng Q, et al. Reduced inflammation and CD4 loss in acute SHIV infection during oral preexposure prophylaxis. J Infect Dis 2012; 206:770-779.
12. Zheng Q, Ruone S, Switzer WM, et al. Limited SHIV env diversification in macaques failing oral antiretroviral preexposure prophylaxis. Retrovirology 2012; 9:40.
13. Shacklett BL, Greenblatt RM. Immune responses to HIV in the female reproductive tract, immunologic parallels with the gastrointestinal tract, and research implications. Am J Reprod Immunol 2011; 65:230-241.
14. Veazey RS, Marx PA, Lackner AA. Vaginal CD4\+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis 2003; 187:769-776.
15. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2:e1312.
16. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360:971-977.
17. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
18. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginalgelforpreventionof HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010; 376:1329-1337.
19. Beer BE, Doncel GF, Krebs FC, et al. In vitro preclinical testing of nonoxynol-9 as potential antihuman immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 2006; 50:713-723.
20. Cone RA, Hoen T, Wong X, et al. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 2006; 6:90.
21. Wira CR, Patel MV, Ghosh M, et al. Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 2011; 65:196-211.
22. Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 2012; 205:358-365.
23. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4\+ T cell depletion and viral replication in SIV infection. Science 1998; 280:427-431.
24. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105:7552-7557.
25. Stone M, Keele BF, Ma ZM, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84:7083-7095.
26. Melkus MW, Estes JD, Padgett-Thomas A, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006; 12:1316-1322.
27. Sun Z, Denton PW, Estes JD, et al. Intrarectal transmission, systemic infection, and CD4\+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007; 204:705-714.
28. Olesen R, Wahl A, Denton PW, Garcia JV. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol 2011; 88:195-203.
29. Denton PW, Garcia JV. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol 2012; 20:268-274.
30. Denton PW, Garcia JV. Humanized mouse models of HIV infection. AIDS Rev 2011; 13:135-148.
31. Denton PW, Othieno F, Martinez-Torres F, et al. One percentage tenofovir applied topically to humanized BLT mice and used accordingtothe CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 2011; 85:7582-7593.
32. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
33. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084-1089.
34. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV gp120. Nat Med 2003; 9:343-346.
35. Veazey RS, Springer MS, Marx PA, et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005; 11:1293-1294.
36. Veazey RS, Ketas TA, Klasse PJ, et al. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci USA 2008; 105:10531-10536.
37. Veazey RS, Ling B, Green LC, et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009; 199:1525-1527.
38. Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306:485-487.
39. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Human Retroviruses 1998; 14 (Suppl 1):S119-S123.
40. Vishwanathan SA, Guenthner PC, Lin CY, et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011; 57:261-264.
41. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
42. Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197-1199.
43. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
44. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367: 399-410.
45. Nakasone T, Murakami T, Yamamoto N. Double oral administration of em-tricitabine/tenofovir prior to virus exposure protects against highly pathogenic simian/human immunodeficiency virus infection in macaques. Jpn J Infect Dis 2012; 65:345-349.
46. Shytaj IL, Norelli S, Chirullo B, et al. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 2012; 8:e1002774.
47. Dobard C, Sharma S, Martin A, et al. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 2012; 86:718-725.
48. Sanders-Beer BE, Spano YY, Golighty D, et al. Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose anti-retroviral therapy. AIDS Res Ther 2011; 8:3.
49. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
50. Malcolm RK, Veazey RS, Geer L, et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012; 56:2251-2258.
51. Malcolm RK, Forbes CJ, Geer L, et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother 2013; 68:678-683.
52. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438:99-102.
53. Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, et al. MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. PLoS Pathog 2012; 8:e1003071.
54. Veazey RS, Klasse PJ, Ketas TJ, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003; 198: 1551-1562.
55. Veazey RS, Ketas TJ, Dufour J, et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010; 202:739-744.
56. Barouch DH, Klasse PJ, Dufour J, et al. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci USA 2012; 109:8694-8698.
57. Fetherston SM, Geer L, Veazey RS, et al. Partial protection against multiple RT-SHIV162P3vaginal challenge ofrhesus macaquesby a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother 2013; 68:394-403.
58. Singer R, Mawson P, Derby N, et al. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med 2012; 4:150ra123.
59. Moss JA, Malone AM, Smith TJ, et al. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother 2012; 56:5952-5960.
60. Johnson TJ, Srinivasan P, Albright TH, et al. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother 2012; 56:1291-1299.
61. Aravantinou M, Singer R, Derby N, et al. The nonnucleoside reverse tran-scription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT infection. AIDS Res Hum Retroviruses 2012; 28:1467-1475.
62. Malcolm RK, Fetherston SM, McCoy CF, et al. Vaginal rings for delivery of HIV microbicides. Int J Womens Health 2012; 4:595-605.